"NOMIS is all about enabling outstanding talent to take on high-risk research."
- Georg Heinrich “Heini” Thyssen, NOMIS Founder
Home / News / NOMIS scientist Björn Lillemeier and colleagues show diabetes drug has unexpected, broad implications for healthy aging

NOMIS scientist Björn Lillemeier and colleagues show diabetes drug has unexpected, broad implications for healthy aging

Computational analysis revealing targets of metformin. (Photo: Salk Institute)

Scientists discover multiple mechanisms at work in widely-used diabetes drug metformin

LA JOLLA—Metformin is the most commonly prescribed type 2 diabetes drug, yet scientists still do not fully know how it works to control blood sugar levels. In a collaborative effort, researchers from the Salk Institute, The Scripps Research Institute and Weill Cornell Medical College have used a novel technology to investigate why it functions so well. The findings, which identified a surprising number of biochemical “switches” for various cellular processes, could also explain why metformin has been shown to extend health span and life span in recent studies. The work was published in Cell Reports on December 3, 2019.

“These results provide us with new avenues to explore in order to understand how metformin works as a diabetes drug, along with its health-span-extending effects,” says Professor Reuben Shaw, co-corresponding author of the paper and the director of Salk’s NCI-designated Cancer Center. “These are pathways that neither we, nor anyone else, would have imagined.”

Continue reading this Salk Institute article

Loading...
Loading...

NOMIS Researchers

Send via Email
Share on Linkedin
Loading...